Physician profile
Calvin C Higgins
NPI 1205934825
$2,383.47
in general payments reported to CMS, 2019-2025
27 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $288 · 2021: $292 · 2022: $255 · 2023: $159 · 2024: $241 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.53 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $340.01 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $228.45 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.79 | 2021-2024 | |
| Lilly USA, LLC | $204.79 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.52 | 2019-2020 | |
| Amarin Pharma, INC. | $104.51 | 2020-2022 | |
| Exact Sciences Corporation | $91.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.59 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $62.60 | 2019 | |
| Kvk-Tech, INC. | $62.38 | 2019 | |
| Amgen INC. | $61.12 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Abbott Laboratories | $50.92 | 2019-2023 | Freestyle Libre |
| Viiv Healthcare Company | $40.93 | 2019-2020 | |
| Astellas Pharma US INC | $33.72 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.83 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $29.66 | 2020 | |
| Sanofi-Aventis U.S. LLC | $26.61 | 2019 | |
| Glaxosmithkline, LLC. | $22.62 | 2019 | |
| Tactile Systems Technology INC | $22.58 | 2025 | Nimbl, Flexitouch Plus |
| Ethicon US, LLC | $20.98 | 2019 | |
| Gilead Sciences, INC. | $16.35 | 2019 | |
| Shield Therapeutics INC | $16.05 | 2024 | |
| Merck Sharp & Dohme LLC | $15.97 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.75 | 2024 | NP Thyroid 60 |
| Allergan, INC. | $12.58 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.